Therapeutic value of pelvic lymph node dissection in high-grade prostate cancer

Abstract

Objective:

This study aimed to assess the therapeutic value of pelvic lymph node dissection (PLND) in high-grade margin-negative prostate cancer without and with lymph node metastases.

Methods:

We retrospectively reviewed cases in the Western Australian radical prostatectomy (RP) database between January 1, 2010, and December 31, 2017. We identified men who had RP only (no PLND) and those had RP with PLND. Further, a subset of high-grade (Gleason score (GS) ⩾8) margin-negative cancers were identified. We assessed the therapeutic impact of PLND in this high-risk but potentially curable subset.

Results:

A total of 5648 prostatectomies were performed, and 1209 of these had concurrent PLND, negative surgical margins, and follow-up prostate-specific antigen (PSA) data. Of 558 men with high-grade margin-negative prostate cancer, 395 men had PLND, while 163 did not. There were significantly more patients with T3/T4 disease in the PLND group compared to those without PLND. Preoperative PSA did not differ significantly between the two groups. However, when stage matched, PLND had no impact on the numbers of men who were cured compared to those who failed surgical intervention.

Conclusion:

PLND has value in staging high-grade prostate cancer but has limited impact on producing a durable PSA cure or avoiding adjuvant therapy.

Level of evidence:

Not applicable for this multicenter audit.

Keywords

Biochemical recurrence lymph nodes prostate cancer prostatectomy prostate-specific antigen

Get full access to this article

View all access options for this article.

References

Sanda

Cadeddu

Kirkby

, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: recommended approaches and details of specific care options. J Urol 2018; 199: 990–997.

Mottet

Van Den Bergh

RCN

Briers

, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243–262.

Rees

Raison

Sheikh

, et al. Is extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literature. Turk J Urol 2016; 42: 240–246.

Fossati

Willemse

Van Den Broeck

, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017; 72: 84–109.

Preisser

Van Den Bergh

RCN

Gandaglia

, et al. Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with D’Amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol 2020; 203: 338–343.

Clark

Parekh

Cookson

, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145–148.

Choo

Kim

, et al. Extended versus standard pelvic lymph node dissection in radical prostatectomy on oncological and functional outcomes: a systematic review and meta-analysis. Ann Surg Oncol 2017; 24: 2047–2054.

Briganti

Chun

FKH

Salonia

, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006–1013.

Yaxley

Dagher

Delahunt

, et al. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018; 36: 15–20.

10.

Furubayashi

Negishi

Uozumi

, et al. Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer. Mol Clin Oncol 2020; 12: 104–110.